{"name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","slug":"gruppo-italiano-malattie-ematologiche-dell-adulto","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-31","label":"Daunorubicine Phase 3 readout (Acute Myeloid Leukaemia)","drug":"Daunorubicine","drugSlug":"daunorubicine","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-06-01","label":"Daunorubicine Phase 3 readout (NMIBC)","drug":"Daunorubicine","drugSlug":"daunorubicine","type":"phase3_readout","sentiment":"neutral"},{"date":"2033-12-01","label":"Daunorubicine Phase 3 readout (Acute Myeloid Leukemia)","drug":"Daunorubicine","drugSlug":"daunorubicine","type":"phase3_readout","sentiment":"neutral"},{"date":"2035-09-01","label":"Daunorubicine Phase 2 readout (Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma)","drug":"Daunorubicine","drugSlug":"daunorubicine","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"immunology","drugs":[{"name":"Cycle 1 Induction","genericName":"Cycle 1 Induction","slug":"cycle-1-induction","indication":"Acute leukemia induction therapy","status":"phase_2"},{"name":"DaunoXome","genericName":"DaunoXome","slug":"daunoxome","indication":"Advanced HIV-associated Kaposi sarcoma","status":"phase_3"},{"name":"Chemotherapy + Imatinib","genericName":"Chemotherapy + Imatinib","slug":"chemotherapy-imatinib","indication":"Acute lymphoblastic leukemia (ALL) in combination with chemotherapy","status":"phase_3"},{"name":"Cycle 7 Consolidation","genericName":"Cycle 7 Consolidation","slug":"cycle-7-consolidation","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia","status":"phase_2"},{"name":"Cytarabine HD","genericName":"Cytarabine HD","slug":"cytarabine-hd","indication":"Acute myeloid leukemia (AML)","status":"phase_3"},{"name":"Dasatinib and blinatumomab","genericName":"Dasatinib and blinatumomab","slug":"dasatinib-and-blinatumomab","indication":"Acute lymphoblastic leukemia (ALL)","status":"phase_2"},{"name":"Daunorubicine","genericName":"Daunorubicine","slug":"daunorubicine","indication":"Acute lymphoid leukemia","status":"discontinued"},{"name":"High-dose anthracycline","genericName":"High-dose anthracycline","slug":"high-dose-anthracycline","indication":"Acute Myeloid Leukemia","status":"phase_2"},{"name":"Ponatinib + Blinatumomab","genericName":"Ponatinib + Blinatumomab","slug":"ponatinib-blinatumomab","indication":"Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Cycle 4 Consolidation","genericName":"Cycle 4 Consolidation","slug":"cycle-4-consolidation","indication":"Other","status":"phase_2"},{"name":"Cycle 5 Consolidation","genericName":"Cycle 5 Consolidation","slug":"cycle-5-consolidation","indication":"Other","status":"phase_2"},{"name":"Ibrutinib 420 mg","genericName":"Ibrutinib 420 mg","slug":"ibrutinib-420-mg","indication":"Other","status":"marketed"},{"name":"Romiplostin","genericName":"Romiplostin","slug":"romiplostin","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Antibiotic and antifungal drugs","genericName":"Antibiotic and antifungal drugs","slug":"antibiotic-and-antifungal-drugs","indication":"Bacterial infections","status":"phase_2"}]}],"pipeline":[{"name":"Antibiotic and antifungal drugs","genericName":"Antibiotic and antifungal drugs","slug":"antibiotic-and-antifungal-drugs","phase":"phase_2","mechanism":"Antibiotic and antifungal drugs work by inhibiting bacterial cell wall synthesis and interfering with fungal cell membrane function.","indications":["Bacterial infections","Fungal infections"],"catalyst":""},{"name":"Cycle 1 Induction","genericName":"Cycle 1 Induction","slug":"cycle-1-induction","phase":"phase_2","mechanism":"Cycle 1 Induction is a chemotherapy regimen used in hematologic malignancies to induce remission through cytotoxic drug combinations.","indications":["Acute leukemia induction therapy","Lymphoma induction therapy","Other hematologic malignancies requiring induction chemotherapy"],"catalyst":""},{"name":"DaunoXome","genericName":"DaunoXome","slug":"daunoxome","phase":"phase_3","mechanism":"DaunoXome is a liposomal formulation of daunorubicin that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cells.","indications":["Advanced HIV-associated Kaposi sarcoma","Acute leukemias (in combination regimens)"],"catalyst":""},{"name":"Chemotherapy + Imatinib","genericName":"Chemotherapy + Imatinib","slug":"chemotherapy-imatinib","phase":"phase_3","mechanism":"This combination uses chemotherapy to kill rapidly dividing cancer cells while imatinib inhibits BCR-ABL and other tyrosine kinases to block leukemic cell proliferation and survival.","indications":["Acute lymphoblastic leukemia (ALL) in combination with chemotherapy","Chronic myeloid leukemia (CML)","Acute myeloid leukemia (AML) with BCR-ABL or other kinase-driven disease"],"catalyst":""},{"name":"Cycle 4 Consolidation","genericName":"Cycle 4 Consolidation","slug":"cycle-4-consolidation","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cycle 5 Consolidation","genericName":"Cycle 5 Consolidation","slug":"cycle-5-consolidation","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cycle 7 Consolidation","genericName":"Cycle 7 Consolidation","slug":"cycle-7-consolidation","phase":"phase_2","mechanism":"This drug targets the CD19 protein on B cells to induce cell death.","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Cytarabine HD","genericName":"Cytarabine HD","slug":"cytarabine-hd","phase":"phase_3","mechanism":"Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Lymphoma","Chronic myeloid leukemia (CML) in blast phase"],"catalyst":""},{"name":"Dasatinib and blinatumomab","genericName":"Dasatinib and blinatumomab","slug":"dasatinib-and-blinatumomab","phase":"phase_2","mechanism":"Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.","indications":["Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia (CML)"],"catalyst":""},{"name":"Daunorubicine","genericName":"Daunorubicine","slug":"daunorubicine","phase":"discontinued","mechanism":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","indications":["Acute lymphoid leukemia","Acute monocytic/monoblastic leukemia","Acute myeloid leukemia, disease","Acute promyelocytic leukemia, FAB M3","Blast crisis of chronic myeloidleukemia"],"catalyst":""},{"name":"High-dose anthracycline","genericName":"High-dose anthracycline","slug":"high-dose-anthracycline","phase":"phase_2","mechanism":"anthracyclines intercalate DNA strands, inhibiting topoisomerase II","indications":["Acute Myeloid Leukemia","Breast Cancer"],"catalyst":""},{"name":"Ibrutinib 420 mg","genericName":"Ibrutinib 420 mg","slug":"ibrutinib-420-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ponatinib + Blinatumomab","genericName":"Ponatinib + Blinatumomab","slug":"ponatinib-blinatumomab","phase":"phase_3","mechanism":"Ponatinib is a tyrosine kinase inhibitor that targets BCR-ABL1, while Blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.","indications":["Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)"],"catalyst":""},{"name":"Romiplostin","genericName":"Romiplostin","slug":"romiplostin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE11d2Znckl3Q0Q4WVlBSzRodDI5Rnp6NXNUMTlscTRZV21oT2FIQXdwam5rUUhLY2w1ODlITFdjTXE2cWJnY25USDBXUG9mUjJKbWViZWNJZ18xZ2syamc?oc=5","date":"2018-06-25","type":"pipeline","source":"NEJM","summary":"Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia - NEJM","headline":"Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_2":8,"phase_3":4,"discontinued":1,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}